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Editorial on the Research Topic
Biomarkers in Neurology
Neurological disorders constitute a major health and socioeconomic problem. They represent
the second cause of death and the leading cause of disability throughout the world. Despite the
implementation of strategies and intervention programs to reduce the burden, over the past 25
years, the incidence, prevalence, mortality, and disability rates of neurological disorders are rising
globally, mainly due to population aging and growth (1). This has placed heavy pressure on
health-care systems pointing out the urgent need to identify new strategies to improve patient
outcomes and reduce health costs by enabling more effective drug development and establishing
a more personalized medicine approach.
Rapid scientific and technical advances have enabled reliable and affordable measurement
of novel biomarkers—biological indicators that objectively measure and evaluate physiological
or pathophysiological processes or pharmacological responses to a therapeutic intervention
(2)—which have been suggested to help assessment and management of patients with neurological
disorders beyond current practice standards (3–5). Evidence suggests a potential variety of
clinical applications, including enhancing diagnostic and prognostic accuracy, improving the
existing decision criteria for early diagnosis and risk stratification, as well as assisting in disease
monitoring, and acting as surrogate endpoints in experimental studies and clinical trials (6–10).
In addition, biomarkers may reliably capture the different aspects of disease heterogeneity and
pathogenesis, helping characterize patients, and thereby informing targeted tailored treatments
and predicting response outcomes to interventions (11–18). However, despite large numbers
of candidate biomarkers have been proposed and extensively evaluated, very few are currently
integrated into routine clinical practice and the quest for novel brain injury markers in still
ongoing (19).
This book aimed at providing an overview of the biomarker landscape in neurological disorders.
The diverse authors discuss established and emerging biomarkers as well as innovative strategies
for identifying novel candidates offering new and unique perspectives. Several articles in this
volume have been focused on Alzheimer’s disease and other neurodegenerative disorders, exploring
potentially relevant genetic signature (Chen et al.) and the pathogenetic and prognostic role of
circulating cytokines (Kim et al.). Importantly, using a methodologically novel approach that
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combines computational prediction and experimental validation,
Yao et al., for the first time, identified VLDLR, an apolipoprotein
E receptor involved in synaptic plasticity, as a circulating
signature for Alzheimer’s disease. Accordingly, several lines of
evidence are pointing toward the added and complementary
value of markers of synaptic function owing to their close link
with cognitive deterioration (20).
Contemporary investigations on microRNAs (miRNAs) (Di
Pietro et al.) and high mobility group box protein 1 (HMGB1)
(Paudel et al.) are also presented, highlighting the fact that these
markers may be risk factors themselves and therefore potential
targets of therapy (21). Diverse contributions recognize the
urgent need for reliable diagnostic and prognostic biomarkers in
peripheral demyelinating diseases (Kamil et al.) and spinal cord
injury (Albayar et al.), with an emphasis on recent advances in
medical knowledge and practice; while other work provides an
opportunity to study established markers, such as neurofilament
light chain, in neonatal neuronal injury (Depoorter et al.), and
to demonstrate the theragnostic potential—capability to identify
and monitor the drug effect on the molecular pathology—
of PAS-positive vacuolated lymphocytes in late-onset Pompe
disease patients treated with ERT (Parisi et al.). Finally, the
role of lipidomic analysis (Sabogal-Guáqueta et al.) and Fourier-
transform infrared imaging spectroscopy and Laser ablation LA-
ICPMS techniques (Ali et al.) in biomarker discovery is outlined.
Overall, this volume offers a unique opportunity to foster
knowledge and innovation in the arena of biomarkers for
neurological disorders, while stimulating testable hypotheses and
the development of a strategic research agenda to accelerate their
incorporation into routine clinical practice.
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